

Lyxor German Mid-Cap MDAX UCITS ETF - Dist

1. FUND INFORMATION

Investment objective

The Lyxor German Mid-Cap MDAX UCITS ETF - Dist is a UCITS compliant exchange traded fund that aims to track the benchmark index MDAX PERF INDEX.

The MDAX PERF INDEX is a capitalisation-weighted index measuring the change in performance of the 50 mid-cap stocks with the highest adjusted market capitalisation listed on the Prime Standard Segment of the German Stock Exchange, after excluding the 40 stocks making up the DAX.

Lyxor ETFs are efficient investment vehicles listed on exchange that offer transparent, liquid and low-cost exposure to the underlying benchmark index.

Trading Information

Place	Opening Hours (GMT)	Currency	Ticker Bloomberg	RIC Reuters	Distribution
Deutsche Boerse (Xetra)*	08:00 / 19:00	EUR	MD4X GY	MD4X.DE	Yes

* First Listing Place of this share class

Ticker: MD4X GY


Main Fund Characteristics

Ticker	MD4X GY
Fund Type	SICAV
Domiciliation	France
UCITS compliant	Yes
ISIN	FR0011857234
Replication method	Indirect (Swap Based)
Securities Lending	No
Full ownership of fund assets	Yes
Share Class Currency	EUR
Inception Date	15/05/2014
Nav per share at inception (EUR)	100
Total Expense Ratio p.a	0.20%
Currency risk	No
NAV per Share (EUR)	173.34
Share AUM (M EUR)	74.83
Total Fund Assets (M EUR)	74.83
Umbrella (M EUR)	24,399.79
Minimum Investment (Share)	1
Income treatment	Distribution
Last Amount (EUR)	2.82
Date of distribution	July & December


Source: Lyxor AM, 30th November 2021

2. Index information


Source: Bloomberg, Lyxor AM, to 30th November 2021



Index Geographical Allocation



Index Sector Allocation



Full name	MDAX PERF INDEX
Exposure	Europe
Asset Class	Equity
Index type	Net Total Return
Currency	EUR
Index Reuters RIC	.MDAXI
Index Bloomberg ticker	MDAX
Further information	-

Top ten constituents

Hannover Rueckversicheru-Reg	5.23%
Leg Immobilien Ag	5.07%
Kion Group Ag	3.86%
Gea Group Ag	3.72%
Carl Zeiss Meditec Ag - Br	3.64%
Nemetschek Ag	3.52%
Commerzbank Ag	3.49%
Knorr-Bremse Ag	3.27%
Evotec Ag	3.05%
Evonik Industries Ag	3.01%

3. ETF Performances

	1 Month	3 Months	6 Months	3 Years	5 Years
Lyxor German Mid-Cap MDAX UCITS ETF - Dist	-2.77%	-5.76%	2.05%	42.69%	59.20%
Benchmark	-2.76%	-5.74%	2.11%	44.50%	62.34%
Tracking Difference	-0.01%	-0.02%	-0.05%	-1.82%	-3.14%
	YTD	2020	2019	2018	2017
Lyxor German Mid-Cap MDAX UCITS ETF - Dist	9.85%	8.26%	30.42%	-17.92%	17.68%
Benchmark	10.05%	8.77%	31.15%	-17.61%	18.08%
Tracking Difference	-0.20%	-0.51%	-0.73%	-0.32%	-0.40%
Tracking Error	-	0.05%	0.02%	0.04%	0.02%

Source: Bloomberg, Lyxor AM, to 30th November 2021

The figures relating to [past performances / simulated past performances / past performances and simulated past performances] refer or relate to past periods and are not a reliable indicator of future results. This also applies to historical market data.

Performances related to distributing ETF are calculated reinvesting dividends into the ETF performance. Performance gap represents the performance differences between the ETF and the Index. The Tracking Error represents the annualised volatility of the performance differences between the ETF and the benchmark.

Changes of benchmark may occur. To compare the track of the ETF with its benchmark, we will use the below indexes:

	From	To	
MDAX PERF INDEX	15/04/2014		
	1Y	3Y	5Y
Fund volatility	12.78%	19.51%	16.97%
Benchmark volatility	12.77%	19.49%	16.95%
Sharpe ratio	1.24	0.67	0.60

Important information for Investors

Parties entering into transactions (such as a derivative or financing transaction) or investing in financial instruments that use an index or a variable interest rate (benchmark) are exposed to the risk that:

- (1) such benchmark may be subject to methodological or other changes which could affect the value of the relevant transaction; or
- (2) (i) may become not compliant with applicable laws and regulations (such as the European Benchmark Regulation), (ii) may cease to be published (possible cessation of LIBOR publication or planned cessation of EONIA both after December 2021), or (iii) the supervisor or administrator of any such benchmark may make a statement that the relevant benchmark is no longer representative, and as a consequence the relevant benchmark may be replaced by another benchmark which may have an adverse and material impact on the economics of the relevant transactions.

You should conduct your own independent investigation and analysis of the potential consequences of any relevant risks such as those mentioned above, particularly in light of the ongoing industry initiatives related to the development of alternative reference rates and the update of the relevant market standard documentation.

Risk Factors

It is important for potential investors to evaluate the risks described below and in the fund prospectus which can be found on www.lyxoretf.com

CAPITAL AT RISK: ETFs are tracking instruments: Their risk profile is similar to a direct investment in the Underlying Index. Investors' capital is fully at risk and investors may not get back the amount originally invested.

REPLICATION RISK: The fund objectives might not be reached due to unexpected events on the underlying markets which will impact the index calculation and the efficient fund replication.

COUNTERPARTY RISK: Investors are exposed to risks resulting from the use of an OTC Swap with BANK OF AMERICA. In-line with UCITS guidelines, the exposure to Societe Generale cannot exceed 10% of the total fund assets.

Physically replicated ETFs may have counterparty risk resulting from the use of a Securities Lending Programme.

UNDERLYING RISK: The Underlying Index of a Lyxor ETF may be complex and volatile. When investing in commodities, the Underlying Index is calculated with reference to commodity futures contracts exposing the investor to a liquidity risk linked to costs such as cost of carry and transportation. ETFs exposed to Emerging Markets carry a greater risk of potential loss than investment in Developed Markets as they are exposed to a wide range of unpredictable Emerging Market risks.

CURRENCY RISK: ETFs may be exposed to currency risk if the ETF is denominated in a currency different to that of the Underlying Index they are tracking. This means that exchange rate fluctuations could have a negative or positive effect on returns.

LIQUIDITY RISK: Liquidity is provided by registered market-makers on the respective stock exchange where the ETF is listed, including Societe Generale. On-exchange liquidity may be limited as a result of a suspension in the underlying market represented by the Underlying Index tracked by the ETF; a failure in the systems of one of the relevant stock exchanges, Societe Generale or other market-maker systems; or an abnormal trading situation or event.

Investor's Notice

**The Total Expense Ratio (TER) covers all costs incurred by the Management Company to manage the underlying assets. It comprises a Management Fee and Structural Costs described as follows. The Management Fee represents the compensation for the Management Company services. The Structural Costs represent the custodian fee, the administrative fee, the audit fee and all other operating costs that will be paid by the Management Company to operate the funds.

This document is of a commercial nature and not of a regulatory nature.

It is each investor's responsibility to ascertain that it is authorised to subscribe, or invest into this product.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice.

Lyxor German Mid-Cap MDAX UCITS ETF is an investment company with Variable Capital (SICAV) incorporated under French Law, and approved by the Autorité des marchés financiers (AMF) in accordance with provisions of the Directive 2009/65/EC (the "2009 Directive").

BANK OF AMERICA and Lyxor International Asset Management S.A.S. recommend that investors carefully study the "Risk Factors" section in the product prospectus and the text headed "Risk and reward profile" in the Key Investor Information Document (KIID). The Dutch-language versions of the prospectus and the KIID, or in any event the English-language versions of these documents, can be consulted free of charge at www.lyxoretf.com or ordered from client-services-etf@lyxor.com.

Shares in a specific UCITS ETF that are managed by an asset manager and purchased on the secondary market cannot usually be sold back to the asset manager directly. Investors must buy and sell shares on a secondary market with the aid of an intermediary, e.g. a stockbroker. This can entail costs. It is also possible that investors will pay more than the current net asset value when buying shares, and will receive less than the current net asset value when selling them.

The current composition of the investment portfolio for the product can be inspected at www.lyxoretf.com. In addition, the indicative net asset value is published on the Reuters and Bloomberg pages for the product, and is sometimes also reported on the websites of the stock exchanges where the product is listed. There is no guarantee that the objective of the fund will be achieved. The fund will not always be able to replicate exactly the performance of the index or indices.

This product carries the risk that capital may be lost. The redemption value of the product may be less than the amount originally invested. In the worst case, investors may lose their entire investment. The index referred to in this document (the "Index") is not sponsored, approved or sold by Société Générale/Lyxor AM. In this context, Société Générale/Lyxor AM accepts no liability whatsoever.

The accuracy, completeness or relevance of information obtained from external sources is not guaranteed, even though the sources concerned can reasonably be considered to be reliable. In compliance with the applicable legislation, Société Générale/Lyxor AM does not accept any liability in this context. The market information contained in this document is based on data at a specific moment in time and can change from time to time.

THIS DOCUMENT IS NOT AN OFFER TO SELL SECURITIES IN THE UNITED STATES OF AMERICA. THE PRODUCT DESCRIBED IN THIS DOCUMENT WILL NOT BE REGISTERED PURSUANT TO THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT") AND CANNOT BE OFFERED OR SOLD IN THE UNITED STATES OF AMERICA WITHOUT REGISTRATION OR WITHOUT EXEMPTION FROM REGISTRATION PURSUANT TO THE U.S. SECURITIES ACT.